The European Commission, on Tuesday 14 July, invited all interested parties to submit their comments on the commitments proposed by Aspen in order to address its concerns about excessive pricing.
Margrethe Vestager, Executive Vice-President in charge of Competition Policy, said the Commission is concerned that Aspen's conduct in this case “amounts to excessive pricing by a dominant firm, which is prohibited by EU competition rules”.
After acquiring the cancer medicines from another...